GENE ONLINE|News &
Opinion
Blog

2018-11-22| PartnerAsia-Pacific

Med X Tech Summit Asia (MEDTEX) 2018 – Overview of Day 1 Program

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

Proudly co-organized by GeneOnline, the global biotech conference brings key opinion leaders comprising healthcare professionals and technology giants under one roof promoting scientific exchange and business partnerships. The event is to be held from Nov 29 – 30, 2018 at the Grande Luxe Banquet, Taipei, Taiwan.

This year, Taipei will bag the honor of hosting MEDTEX 2018, a showcase event displaying the digital revolution in the healthcare industry. This event is as an ideal opportunity to witness the latest advances in next generation bio-therapeutics and breakthroughs in precision medicine. MEDTEX will serve as the focal point where cutting-edge research and technology meet business perspectives. Expert talks will be delivered on various hot topics encompassing AIoT, Immune-Oncology, Blockchain, Big data, Gene editing and Cell therapy among others.

The following are some of the major highlights on the first day of the conference.

The guests will be welcomed with opening remarks from two honorary figures, Mr. Jia-Chyuan Su, President, Legislative Yuan (R.O.C) and Dr. Chi-Huey Wong, Distinguished Research Fellow at Academia Sinica.

1) The global healthcare industry is constantly evolving with the advent of new technologies and collaborative participation of many international players. Therefore, the inaugural program of the session is titled CEO Perspectives where a panel of distinguished speakers from various premier industries would discuss on the topic “Foreseeing the Future of Healthcare – Cross-industry Opportunities and Challenges of Healthcare Advances”. The goal is to garner key insights on cross-industry cooperation opportunities, challenges and strategies. The discussion will be moderated by Simon Chang, the Chairman of IBMI. The key members of the panel include Murakami Sei (Hitachi), Birgit Reitmaier (Merck), Larry Merizalde (Teva), Eunice Chiu (NVIDIA) and Harry Yang (Qisda).

2) The second panel discussion would focus on the new breakthroughs in the rapidly advancing fields of Immuno-oncology, Next generation Biotherapeutics and Gene editing. The discussion will be moderated by Clifford Chao, Vice President of the China Medical University. The speakers in the panel include Seigo Izumo (Takeda Pharma), Wise Young (StemCyte), David DiGiusto (Semma Therapeutics) and Tony J.C. Wang, (Columbia University Medical Center). The discussion also includes fireside chats from Trevor Martin (Mammoth Biosciences) and Chris Shu (Pacific 8 Ventures).

3) The final discussion session on the first day is titled Delivering Personalized Healthcare through Precision Medicine. The discussion will be moderated by Yun Yen, the Chair Professor of Taipei Medical University. The speakers in the panel include Alireza Haghighi (Harvard Medical School), Colin Collins (Vancouver Prostate Centre) and Liang-Yeu Lenny Chen (IBM Watson Health).

Interesting talks and discussions are also scheduled for the second day of the event. Follow GeneOnline for more details.

To register for the event, please visit

https://www.eventbrite.com/e/medtex-med-x-tech-summit-asia-2018-tickets-50897919046

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Pharmacogenomics (PGx): Tailoring Medicine to Your Genes
2024-04-01
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top